InvestorsHub Logo
Followers 10
Posts 500
Boards Moderated 0
Alias Born 09/04/2014

Re: None

Monday, 10/24/2016 4:55:20 PM

Monday, October 24, 2016 4:55:20 PM

Post# of 1121
Volume in September of this year was caused by positive results of a study involving CaPre. $ACST is waiting on FDA approval. When it does, $ACST will skyrocket. This is a reply from an investor relations rep posted on another discussion board.

http://www.stockhouse.com/companies/bullboard/v.apo/acasti-pharma-inc?postid=25238430

Email reply from Jessica Dyas Acasti Pharma Account Manager

CaPre is not yet approved by the FDA. The results of the study support Acasti’s strategy to pursue the FDA’s 505(b)(2) regulatory pathway for approval. The 505(b)(2) regulatory pathway allows Acasti to streamline the overall development program required to support a NDA (New Drug Application) by relying on the safety data of an approved drug.

We have not given any additional information regarding timing.

Thank you for your inquiry.

Jessica Dyas

Account Manager

Canale Communications Inc.

P: 619.849.5385

C: 619.322.5969

Sent: Wednesday, September 14, 2016 3:45 PM
To: Jessica Dyas <jessica@canalecomm.com>


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News